Laverock Therapeutics Secures Additional Seed Funding
Deal News | Jun 30, 2025 | Calculus Capital
Laverock Therapeutics, a biotechnology company focused on innovative therapeutic solutions, has successfully closed an additional round of seed funding. The funding was led by Calculus Capital, a prominent private equity firm. This financial injection is earmarked for the advancement of Laverock's key milestones in the development of its therapeutic portfolio.
Sectors
- Biotechnology
- Private Equity
Geography
- United Kingdom – Calculus Capital is based in the United Kingdom, indicating that the funding activities likely have UK involvement.
Industry
- Biotechnology – The primary focus of Laverock Therapeutics is on developing novel therapeutic solutions, placing the company in the Biotechnology sector.
- Private Equity – Calculus Capital, a private equity firm, leads the new funding round for Laverock Therapeutics, thus engaging in Private Equity investment activities.
Financials
- Undisclosed – The article mentions an additional seed funding round but does not disclose the financial amount.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Laverock Therapeutics | Target Company | Companies | A biotechnology firm focusing on innovative therapeutic developments. |
| Calculus Capital | Lead Investor | Companies | A UK-based private equity firm leading the seed funding round for Laverock Therapeutics. |